Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taxotere approved for prostate cancer

Executive Summary

Aventis' Taxotere (docetaxel) adds indication for treatment of hormone refractory prostate cancer in combination with prednisone May 19. Revised 1labeling includes data from 335 patients showing median survival advantage of 2.4 months versus mitoxantrone (Amgen/OSI's Novantrone). Taxotere is first drug to show survival benefit in that population, FDA says. Aventis is also investigating Taxotere as first-line prostate cancer therapy...

You may also be interested in...



Aventis Taxotere Approved For Breast Cancer; Lowers Relapse Chance 25.7%

Aventis added an adjuvant node-positive breast cancer indication for Taxotere Aug. 18

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel